Top

BMC Nephrology

Published in:

Open Access 01-12-2023 | Research

The correlation between serum uric acid and diabetic kidney disease in type 1 diabetes patients in Anhui, China

Authors: Jun Jiang, Xiaowan Zhou, Lei Lan, Wei Ren

Published in: BMC Nephrology | Issue 1/2023

Abstract

Background/Aim

To assess the correlation between serum uric acid (UA) level and diabetic kidney disease (DKD) in Type 1 diabetes (T1DM) patients in Anhui, China.

Methods

A total of 231 patients diagnosed with T1DM in our hospital were enrolled between January 2014 and December 2016. Urinary albumin-creatinine ratio (ACR) in patients with hyperuricemia was compared with those without hyperuricemia. The relationship between serum UA level and urinary ACR was examined by Spearman's correlational analysis and multiple stepwise regression analysis. The binary logistic multivariate regression analysis was performed to analyze the correlated factors for type 1 DKD.

Results

The average serum UA levels were 257.7 [215.0, 338.0]μmol/L. The median levels of urinary ACR were significantly higher in patients with hyperuricemia than those without hyperuricemia. In multiple stepwise regression analysis, Serum UA levels were positively correlated with the urinary ACR. The logistic multivariate regression analysis showed that hyperuricemia (OR: 5.24, 95% CI: 1.40—19.65, P = 0.014) had an independent positive correlation with DKD in T1DM patients, and the odds of Serum UA to DKD were both elevated as the serum UA levels rose no matter whether adjustment for traditional confounders. The area under the receiver operating characteristic curve was 0.62 (95% CI: 0.55–0.70) in assessing the discrimination of the serum UA level for DKD in T1DM patients.

Conclusions

In Chinese patients with T1DM, the serum UA level is positively correlated with urinary ACR and DKD. The correlation between Serum UA and DKD gradually increases with serum UA levels. Serum UA level is not a good predictor for DKD in T1DM patients. Serum UA may directly contribute to initiating DKD, while it has little direct but an indirect effect on an already established DKD in T1DM patients.

Available only for authorised users

Wadén J, Forsblom C, Thorn LM, Saraheimo M, Rosengård-Bärlund M, et al. Adult stature and diabetes complications in patients with type 1 diabetes: the FinnDiane Study and the diabetes control and complications trial. Diabetes. 2009;58(8):1914–20. https://doi.org/10.2337/db08-1767.CrossRefPubMedPubMedCentral

Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–14. https://doi.org/10.1016/S0140-6736(12)60572-8.CrossRefPubMed

Diabetes Prevention Program Research Group. Changes in albumin excretion in the diabetes prevention program. Diabetes Care. 2009;32(4):720–5. https://doi.org/10.2337/dc08-1400.CrossRefPubMedCentral

Weng J, Zhou Z, Guo L, Zhu D, Ji L, et al. Incidence of type 1 diabetes in China, 2010–13: population based study. BMJ. 2018;360:j5295. https://doi.org/10.1136/bmj.j5295.CrossRefPubMedPubMedCentral

Wang Y, Tan J, Liu D, et al. The Association of UNC13B Gene Polymorphisms and Diabetic Kidney Disease in a Chinese Han Population. Med Sci Monit. 2019;25:8527–33. https://doi.org/10.12659/MSM.919930.CrossRefPubMedPubMedCentral

Jin L, Wang T, Jiang S, et al. The Association of a Genetic Variant in SCAF8-NKSR3 with Diabetic Kidney Disease and Diabetic Retinopathy in a Chinese Population. J Diabetes Res. 2017;2017:6542689. https://doi.org/10.1155/2017/6542689.CrossRefPubMedPubMedCentral

Jenny PD, Michelle S, Sherita HG, et al. Racial/Ethnic Trends in Prevalence of Diabetic Kidney Disease in the United States. Kidney Int Rep. 2019;4(2):334–7. https://doi.org/10.1016/j.ekir.2018.10.018.CrossRef

Ponticelli C, Podestà MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease [J]. Kidney Int. 2020;98(5):1149–59. https://doi.org/10.1016/j.kint.2020.05.056.CrossRefPubMed

Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout [J]. Lancet. 2021;397(10287):1843–55. https://doi.org/10.1016/S0140-6736(21)00569-9.CrossRefPubMed

10.

Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors [J]. Nat Rev Rheumatol. 2020;16(7):380–90. https://doi.org/10.1038/s41584-020-0441-1.CrossRefPubMed

11.

Dong X, Zhang H, Wang F, Liu X, Yang K, Tu R, Wei M, Wang L, Mao Z, Zhang G, Wang C. Epidemiology and prevalence of Hyperuricemia among men and women in Chinese rural population: the henan rural cohort study. Mod Rheumatol. 2020;30(5):910–20. https://doi.org/10.1080/14397595.2019.1660048.CrossRefPubMed

12.

Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: the national health and nutrition examination survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–9. https://doi.org/10.1002/art.40807.CrossRefPubMedPubMedCentral

13.

Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving H-H. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009;58(7):1668–71. https://doi.org/10.2337/db09-0014.CrossRefPubMedPubMedCentral

14.

Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010;25:1865–9. https://doi.org/10.1093/ndt/gfp740.CrossRefPubMedPubMedCentral

15.

Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, et al. High-normal Serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010;33(6):1337–43. https://doi.org/10.2337/dc10-0227.CrossRefPubMedPubMedCentral

16.

Pilemann-Lyberg S, Lindhardt M, Persson F, Andersen S, Rossing P. Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. J Diabetes Complications. 2018;32(5):470–3. https://doi.org/10.1016/j.jdiacomp.2018.02.002.CrossRefPubMed

17.

Mauer M, Doria A. Uric acid and diabetic nephropathy risk. Contrib Nephrol. 2018;192:103–9.CrossRefPubMedPubMedCentral

18.

Ahola AJ, Sandholm N, Forsblom C, Harjutsalo V, Dahlström E, et al. The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes. Kidney Int. 2017;91(5):1178–85. https://doi.org/10.1016/j.kint.2016.CrossRefPubMed

19.

Sascha Pilemann-Lyberg, Tine Willum Hansen, Frederik Persson, Simone Theilade, Tarunveer Singh Ahluwalia, et al. Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. Nephrol Dial Transplant, 2018:1–8. https://doi.org/10.1093/ndt/gfy076.

20.

Jiang J, Lan L, Zhou X, Peng L, Ren W. The relationship between haemoglobin level and type 1 diabetic nephropathy in Han patients in Anhui. China Intern Med J. 2018;48(7):830–5. https://doi.org/10.1111/imj.13767.CrossRefPubMed

21.

American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Supplement-1):S17–38. https://doi.org/10.2337/dc22-S002.CrossRef

22.

American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement-1):S46–59. https://doi.org/10.2337/dc22-S004.CrossRef

23.

Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients [J]. N Engl J Med. 1984;311:89–93. https://doi.org/10.1056/NEJM198407123110204.CrossRefPubMed

24.

Feig DI, Soletsky B, Johnson RJ. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA. 2008;300(8):924–32.CrossRefPubMedPubMedCentral

25.

Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism[J]. Am J Physiol Renal Physiol. 2002;282(6):F991-997.CrossRefPubMed

26.

Sánchez-Lozada LG, Tapia E, Santamaría J, et al. Mild Hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats[J]. Kidney Int. 2005;67(1):237–47.CrossRefPubMed

27.

Perkins BA, Bebu I, de Boer IH, et al. Risk factors for kidney disease in type 1 diabetes. Diabetes Care. 2019;42(5):883–90. https://doi.org/10.2337/dc18-2062.CrossRefPubMedPubMedCentral

28.

Tsion A, Eric DP, Neha JP, et al. The Association between Triglycerides and Incident Cardiovascular Disease: What Is “Optimal”? J Clin Lipidol. 2020;14(4):438-447.e3. https://doi.org/10.1016/j.jacl.2020.04.009.CrossRef

29.

Aktas G, Khalid A, Kurtkulagi O, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study[J]. Postgrad Med. 2022;134(3):297–302. https://doi.org/10.1080/00325481.2022.2039007.CrossRefPubMed

30.

Aktas G, Kocak MZ, Bilgin S, et al. Aging Male, 2020, 23 (5):1098–1102. https://doi.org/10.1080/13685538.2019.1678126.

31.

Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. PERL Study Group. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020;382:2493–503. https://doi.org/10.1056/NEJMoa1916624.CrossRefPubMedPubMedCentral

32.

Kimura K, Hosoya T, Uchida S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810.CrossRefPubMed

33.

Yang Z, Xiaohua W, Lei J, et al. Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells[J]. Am J Physiol Renal Physiol. 2010;299(2):F336-346.CrossRefPubMed

34.

Gherghina ME, Peride I, Tiglis M, et al. Uric acid and oxidative stress - relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci. 2022;23(6):3188. https://doi.org/10.3390/ijms23063188.CrossRefPubMedPubMedCentral

35.

Jung SW, Kim SM, Kim YG, et al. Uric acid and inflammation in kidney disease[J]. Am J Physiol Renal Physiol. 2020;318(6):F1327–40. https://doi.org/10.1152/ajprenal.00272.2019.CrossRefPubMed

36.

Dissanayake LV, Spires DR, Palygin O, et al. Effects of uric acid dysregulation on the kidney[J]. Am J Physiol Renal Physiol. 2020;318(5):F1252–7. https://doi.org/10.1152/ajprenal.00066.2020.CrossRefPubMedPubMedCentral

37.

Bilgin S, Kurtkulagi O, Atak Tel BM, et al. Does C-reactive protein to serum Albumin Ratio correlate with diabetic nephropathy in patients with Type 2 dIabetes MEllitus? The CARE TIME study[J]. Prim Care Diabetes. 2021;15(6):1071–4. https://doi.org/10.1016/j.pcd.2021.08.015.CrossRefPubMed

38.

Kang D-H, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease[J]. J Am Soc Nephrol. 2002;13(12):2888–97.CrossRefPubMed

39.

Sánchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283(5):F1105–10.CrossRefPubMed

40.

Liu M, Ning X, Li R, et al. Signalling pathways involved in hypoxia-induced renal fibrosis[J]. Cell Mol Med. 2017;21(7):1248–59.CrossRef

41.

Lytvyn Y, Škrti M, Yang GK, et al. Plasma uric acid effects on glomerular hemodynamic profile of patients with uncomplicated Type 1 diabetes mellitus [J]. Diabet Med. 2016;33(8):1102–11.CrossRefPubMed

42.

Lytvyn Y, Har R, Locke A, et al. Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes [J]. Diabetes. 2017;66(7):1939–49.CrossRefPubMed

43.

Matheus A, Tibiriçá E, da Silva P, et al. Uric acid levels are associated with microvascular endothelial dysfunction in patients with Type 1 diabetes [J]. Diabet Med. 2011;28(10):1188–93.CrossRefPubMed

Title: The correlation between serum uric acid and diabetic kidney disease in type 1 diabetes patients in Anhui, China
Authors: Jun Jiang
Xiaowan Zhou
Lei Lan
Wei Ren
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-023-03302-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background/Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Proteomic profiling of protein expression changes after 3 months-exercise in ESRD patients on hemodialysis

Correction: Use machine learning to help identify possible sarcopenia cases in maintenance hemodialysis patients

Different outcomes following parathyroidectomy in patients with uremic tumoral calcinosis: two case reports

A survival case of visceral disseminated varicella zoster virus infection in a patient with systemic lupus erythematosus

Tubular basement membrane deposits after allogeneic hematopoietic stem cell transplantation

Extra-capillary cell proliferation and diabetic nephropathy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials